DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Celontin (Methsuximide) - Summary

 
 



CELONTIN SUMMARY

Celontin (methsuximide) is an anticonvulsant succinimide, chemically designated as N,2-Dimethyl-2-phenylsuccinimide.

Celontin is indicated for the control of absence (petit mal) seizures that are refractory to other drugs.


See all Celontin indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Celontin (Methsuximide)

Epilepsy - why do seizures sometimes continue after surgery?
Source: Epilepsy News From Medical News Today [2016.11.21]
New research from the University of Liverpool, published in the journal Brain, has highlighted the potential reasons why many patients with severe epilepsy still continue to experience seizures...

Should video monitors be used to detect night-time seizures in patients with epilepsy?
Source: Epilepsy News From Medical News Today [2016.10.06]
Following a sudden death at a residential care unit, the Dutch Health and Care Inspectorate advised to intensify the use of video monitoring at the unit.

Febrile Seizures
Source: MedicineNet Roseola Specialty [2016.09.13]
Title: Febrile Seizures
Category: Diseases and Conditions
Created: 5/9/2008 12:00:00 AM
Last Editorial Review: 9/13/2016 12:00:00 AM

Antidepressants Linked to First-Time Seizures
Source: MedicineNet mirtazapine Specialty [2015.04.09]
Title: Antidepressants Linked to First-Time Seizures
Category: Health News
Created: 4/9/2015 12:00:00 AM
Last Editorial Review: 4/9/2015 12:00:00 AM

Scientists track down possible new treatment for epilepsy
Source: Epilepsy News From Medical News Today [2016.09.27]
Increasing the concentration of specific fats in the brain could suppress epileptic seizures.

more news >>

Published Studies Related to Celontin (Methsuximide)

Effective and safe but forgotten: methsuximide in intractable epilepsies in childhood. [2001.03]
The efficacy and safety of methsuximide (MSM) was evaluated in children with intractable epilepsies in a prospective uncontrolled study. MSM was added to the therapeutic regimen of 112 children with intractable epilepsy under inpatient conditions, all of whom were therapeutically refractory to various first-line antiepileptic drugs (AED) or combinations of other AED...

Methsuximide lowers lamotrigine blood levels: A pharmacokinetic antiepileptic drug interaction. [2000.05]
PURPOSE: To determine whether methsuximide (MSM) affects lamotrigine (LTG) blood levels and whether any change is of clinical significance... CONCLUSIONS: Although MSM is a valuable add-on, broad-spectrum drug when used in combination with LTG, adjustment of the LTG dose may be necessary when MSM is started or stopped, to allow for the fact that MSM lowers LTG blood levels.

Serum protein binding of desmethyl-methsuximide. [1999.07]
Serum protein binding of desmethyl-methsuximide (DM-MSM) in serum from 23 patients on polytherapy were determined using ultrafiltration and high-performance liquid chromatography. Desmethyl-methsuximide, The active metabolite of methsuximide (MSM), was found to have a moderate protein binding ranging between 45% and 60%..

Methsuximide therapy of juvenile myoclonic epilepsy. [1996.03]
Currently valproic acid is considered to be the drug of first choice for juvenile myoclonic epilepsy (JME) resulting in a 70-90% control rate for all seizure types associated with JME. In those situations where valproic acid fails to control seizure activity, results in unacceptable side-effects, or is declined due to potential side-effects, an alternative effective monotherapy would be desirable...

Methsuximide for intractable childhood seizures. [1991.02]
Methsuximide was added to the therapeutic regimens of 25 children with intractable epilepsy. In 15 patients the drug was well tolerated and resulted in a 50% or greater reduction in seizure frequency... Methsuximide is frequently overlooked and may be an effective adjunctive antiepileptic for children with intractable seizures.

more studies >>


Page last updated: 2016-11-21

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015